Latest Tiziana Life Sciences News & Updates

See the latest news and media coverage for Tiziana. We track all announcements, press releases, and industry mentions in real time, all in one place.

Tiziana Life Sciences (Tiziana)

Clinical-stage biopharmaceutical company developing immunotherapies for neurological and inflammatory conditions

tizianalifesciences.com

Headquarters: London, United Kingdom
Company type: Public company
Number of employees: 10–50
Industry: Pharmaceuticals

Last updated Today

Latest news about Tiziana Life Sciences (Tiziana)

In short: Tiziana advanced its intranasal foralumab pipeline, reporting reduced brain inflammation in MSA and completing MS trial enrollment.

Company announcements

July 31 Tiziana

Tiziana reports reduction in brain inflammation in third MSA patient

PET imaging showed up to 34% reduction in SUV and 26% in SUVR in affected brain regions, consistent with prior patients.

June 25 Tiziana

Tiziana Life Sciences announces last patient dosed in Phase 2 INFORM-MS trial

The milestone marks completion of dosing for the multiple sclerosis trial.

June 15 Tiziana

Tiziana Life Sciences announces executive chairman's share purchase

Mr. Gabriele Cerrone bought 15,000 common shares at $1.11, increasing his stake to 34.89%.

May 21 Tiziana

Tiziana Life Sciences fully enrolls Phase 2 multiple sclerosis trial

The randomized, double-blind, placebo-controlled trial evaluates intranasal foralumab in 48 patients with non-active secondary progressive MS.

Media coverage

Yesterday RTTNews

Tiziana Signs MOU With KAIMRC To Advance Foralumab MS Trials; Stock Up

The collaboration aims to support a planned clinical trial evaluating a combination of Tiziana's proprietary intranasal foralumab with existing anti-CD20 therapy in patients with relapsing-remitting...

September 15 MSN

Tiziana Life Sciences consensus price target decreased by 11.11% to $8.16

The average one-year price target for Tiziana Life Sciences (NASDAQCM:TLSA) has been revised to $8.16 / share. This is a decrease of 11.11% from the...

August 20 Tickeron

Why Is Tiziana Life Sciences (TLSA) Stock Up +7.48% Today?

Tiziana Life Sciences Ltd (TLSA), a clinical-stage biotechnology company developing intranasal immunomodulation therapies led by its fully human anti-CD3 monoclonal antibody, foralumab, saw its stock...

August 11 Yahoo Finance

Tiziana Life Sciences Ltd (TLSA)

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 p.m. to 4 a.m. ET, Sunday through Thursday, when...

Never miss news about Tiziana

Track Tiziana and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Tiziana competitors & trending companies

Browse news for competitors to Tiziana and other trending companies.